Bristol-Myers Squibb Co.

NYSE:BMY  
64.86
-0.18 (-0.28%)
4:23:20 PM EDT: $64.81 -0.05 (-0.08%)
Products, Litigation, Regulatory

Dr.Reddy's Settles U.S. Revlimid Capsules Patent Litigation With Celgene

Published: 09/17/2020 11:22 GMT
Bristol-Myers Squibb Co. (BMY) - Announces Settlement of U.S. Revlimid (lenalidomide) Capsules Patent Litigation With Celgene.
Celgene to Provide Co With License to Sell Volume-limited Amounts of Generic Lenalidomide Capsules in U.S.agreed-upon Sales Volume Percentages Confidential.
Also Licensed to Sell Generic Lenalidomide in U.S. Without Volume Limit.
License to Sell Volume-limited Amounts of Generic Lenalidomide Capsules in U.S. Begins on Confidential Date After March 2022.